ProQR Doses First Patient in Phase 1 Study for Next-Gen Liver Disease Drug AX-0811
PRQR sits 54% above its 52-week low of $1.33.
Summary
ProQR Therapeutics announced the dosing of the first participant in its Phase 1 clinical trial for AX-0811, a next-generation RNA editing therapy for cholestatic liver diseases, and will host an investor event on September 30, 2026.
Key Events · Product Development and Regulatory · PRQR
-
First Patient Dosed in Phase 1 Study
ProQR Therapeutics has dosed the first participant in its Phase 1 clinical trial for AX-0811, an investigational RNA editing oligonucleotide for cholestatic liver diseases, including biliary atresia.
-
Next-Generation Therapy
AX-0811 is described as a next-generation, AI-discovered therapy with preclinical data demonstrating greater potency and a longer half-life compared to the previous candidate, AX-0810.
-
Investor & Analyst Event Scheduled
The company will host a virtual investor and analyst educational event on September 30, 2026, to discuss NTCP modulation in liver disease, review AX-0810 data, and outline the clinical strategy for AX-0811.
-
Upcoming Data Readout
Initial Phase 1 target engagement data for AX-0811's first two cohorts are anticipated in early January 2027.
Analysis · PRQR · Life Sciences
This filing marks a significant pipeline advancement for ProQR, moving its next-generation RNA editing candidate, AX-0811, into human trials. The drug, which showed improved preclinical potency over its predecessor, targets cholestatic liver diseases. The upcoming investor event will provide further details on the program and its potential, building on recent positive clinical data for AX-0810 and substantial insider buying.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRQR was trading at $2.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283.1M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.